CNSP实时信号 | 通过Getagraph.com最大化利润

Live Chart Being Loaded With Signals

Commentary (2 May 2024 @ 04:00):

CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors...

Stats
今日成交量	69 319.00
平均成交量	321 237
市值	2.32M
EPS	$0 ( 2024-04-01 )
下一个收益日期	( $0 ) 2024-05-13
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.0200
ATR14	$0.00500 (2.36%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-08	Mahery Amy	Buy	17 500	Restricted Stock Units
2024-04-08	Mahery Amy	Buy	17 500	Option to purchase common stock
2024-04-08	Keyes Jeffry R.	Buy	17 500	Restricted Stock Units
2024-04-08	Keyes Jeffry R.	Buy	17 500	Option to purchase common stock
2024-04-08	Gumulka Jerzy	Buy	17 500	Restricted Stock Units

INSIDER POWER
95.24
Last 96 transactions
Buy: 4 147 286 \| Sell: 1 591 936

音量相关性

長: -0.25 (neutral)

短: -0.33 (neutral)

Signal:(49.609) Neutral

CNS Pharmaceuticals Inc 相关性

10 最正相关
TDAC	0.958
GAINL	0.947
THMO	0.941
HUSN	0.939
UK	0.935
RMRM	0.924
BIOL	0.924
KBSF	0.922
GRNV	0.921
APOP	0.918

10 最负相关
BOCH	-0.96
SHSP	-0.937
HEES	-0.92
LMST	-0.914
LOPE	-0.914
KBWP	-0.908
PI	-0.908
LMRK	-0.905
HOLX	-0.905
INNV	-0.901

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

CNS Pharmaceuticals Inc 相关性 - 货币/商品

-0.03
( neutral )

-0.05
( neutral )

0.00
( neutral )

-0.16
( neutral )

CNS Pharmaceuticals Inc 财务报表

Annual	2023
营收:	$0
毛利润:	$-4 134.00 (0.00 %)
EPS:	$-5.00

FY	2023
营收:	$0
毛利润:	$-4 134.00 (0.00 %)
EPS:	$-5.00

FY	2022
营收:	$0
毛利润:	$-11 756.00 (0.00 %)
EPS:	$-11.22

FY	2021
营收:	$0.00
毛利润:	$0.00 (0.00 %)
EPS:	$-15.34

Financial Reports:

No articles found.

CNS Pharmaceuticals Inc

CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, an anthracycline that is in Phase I and II clinical trials that is used for the treatment of glioblastoma multiforme. It has license agreements with Houston Pharmaceuticals, Inc. and The University of Texas M.D. Anderson Cancer Center, as well as Animal Life Sciences, LLC; and a development agreement with WPD Pharmaceuticals Inc., as well as a collaboration agreement with Reata Pharmaceuticals, Inc. The company was incorporated in 2017 and is based in Houston, Texas.